Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000947871-25-000624·Chemomab Therapeutics Ltd.
Schedule 13D ownership disclosure
CHEMOMAB THERAPEUTICS LTD
Ordinary Shares, no par value. American Depository Shares, each of which represents twenty Ordinary Shares, no par value · CUSIP: 16385C104
Event date: 2025-06-18
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIPReported CIK 0001569821
Shares: 969,807.00 · Class: 4.8%
- ORBIMED ISRAEL GP LTD.Reported CIK 0001569590
Shares: 969,807.00 · Class: 4.8%
- CHIMOVITS EREZReported CIK 0001706399
Shares: 969,807.00 · Class: 4.8%
- GORDON CARL LReported CIK 0001282930
Shares: 969,807.00 · Class: 4.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000624
- Form type
- SCHEDULE 13D/A
- Filer
- Chemomab Therapeutics Ltd.
- CIK
- CIK 1534248
- Filed
- Jun 23, 2025
- Reporting period
- Jun 18, 2025
- Description
- Schedule 13D beneficial ownership